🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Psychedelic Alphaの取材を受けました（無料・日英対応）。精神展開剤研究を始めた経緯や今後について話しています。 I was interviewed by Psychedelic Alpha (free, JP/EN). I shared how I started psychedelic research and future plans.

Psychedelic Alpha readers are deeply divided over what to expect from the Trump administration re: psychedelics-related reforms and action.

In a recent interview, leading Japanese psychedelics researcher Hiroyuki Uchida told us about how he became interested in psilocybin research. Read more in the full interview, available in both English and Japanese: psychedelicalpha.com/news/psychedel…

Pα+ Psychedelic Bulletin 198 🗓️ Long-term Spravato data 💊 MAHA attacks psych meds 🌬️ Beckley’s 5-MeO-DMT + SSRI shows promise 🇪🇺 EU funds ‘Psychedelic Renaissance’ 🍃 DEA okays ayahuasca church 📔 Delays, deals & new journals psychedelicalpha.com/news/p%ce%b1-p…

Matt Zorn, the Government’s Former Adversary, Is Now Its Psychedelics Czar Matt Zorn made his name suing federal agencies over cannabis and psychedelics policy. Now, he’s inside the system as Deputy General Counsel at HHS, with a psychedelics mandate. psychedelicalpha.com/news/matt-zorn…

🔐 Paywall Temporarily Lifted If you would like to read this story, the paywall has been temporarily lifted. Read the full piece via the link in the post:

🔐 If you would like to read our story for yourself, the paywall has been temporarily lifted: psychedelicalpha.com/news/matt-zorn…

ICYMI: Matt Zorn, the Government’s Former Adversary, Is Now Its Psychedelics Czar The man who made his name suing federal agencies over cannabis and psychedelics policy is now working on the inside. The full story: psychedelicalpha.com/news/matt-zorn…

New Data Offers Look at Spravato’s Long-Term Use, Highlights Opportunity for Psychedelics New long-term data from Janssen’s SUSTAIN-3 study show that many patients took the drug multiple times a month for years, despite logistical burdens. The findings could strengthen the case

MAHA Report Slams Psychiatric Drug Use Among America’s Youth The MAHA Report sharply criticises the widespread use of psychiatric drugs among American youth, underscoring growing political skepticism toward chronic psychiatric medication. It is clear that the MAHA

New: We take a closer look at Gilgamesh's positive Phase 2a results of GM-2505 (aka bretisilocin, a serotonergic psychedelic) in major depressive disorder (MDD) & speak to company execs The results should provide a welcome catalyst for the field. psychedelicalpha.com/news/gilgamesh…

Texas is on the verge of launching the largest publicly funded psychedelic research initiative in U.S. history: a $50 million public-private partnership to support FDA-approvable ibogaine trials. We take a look at the plan and questions that remain. psychedelicalpha.com/news/can-a-sta…

Psychedelic Bulletin 199: 📌 New CEO Tapped as Gracias & Hohn Close In on Lykos Therapeutics Takeover 📌 Data Reveals <100 Patients Received Psychedelics in Australia During First 18 Months 📌 Ibogaine Bill Clears Texas Legislature Amid THC Crackdown psychedelicalpha.com/news/p%ce%b1-p…

After Controversy, the Psilocybin & Religious Leaders Study Is Finally Published After years of anticipation and controversy, Johns Hopkins and NYU have released their research on the effects of psilocybin on religious leaders via a journal article in Psychedelic Medicine. The

Psychedelic Alpha has learned that Elon Musk ally Antonio Gracias and ‘Europe’s most feared investor’ Sir Christopher Hohn are close to closing the first phase of a $100M takeover of MDMA drug developer Lykos Therapeutics. A $50M initial round, split between the pair, will be

BREAKING: Czech Republic Set to Allow Medical Use of Psilocybin If approved by the Senate next month, it will become the third country in the world to allow access to a psychedelic ahead of conventional marketing approval.

Data Reveals Fewer than 100 Patients Received Psychedelics in Australia During First 18 Months of Access We obtained data via Australia's Freedom of Information legislation to understand how many patients have accessed MDMA and psilocybin in the country since its limited

BREAKING: atai Moves to Acquire Beckley, If Phase 2b 5-MeO-DMT Data Delivers $ATAI has struck an option-like deal with Beckley Psytech: it will acquire the latter in an all-share transaction should its Phase 2b readout meet prespecified criteria. psychedelicalpha.com/news/breaking-…

After a sluggish start, $ATAI stock is up 11.5% today. On the monthly it's up 72%.

📫 Each Sunday we send our Psychedelic News Feed to 15k+ psychedelic insiders. Bookmark the live Feed and subscribe for free to get the Sunday roundup: psychedelicalpha.com/live 🔗 Links to all the stories mentioned above can be found there, too.